Morgan Stanley Medicinova Inc Transaction History

Morgan Stanley

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Oct 17, 2024	BUY	$1.28 - $1.65 $56 - $72	44 New	44 $0
Q4 2023 Aug 16, 2024	BUY	$1.38 - $2.06 $60 - $90	44 New	44 $0
Q4 2023 Feb 13, 2024	SELL	$1.38 - $2.06 $8,513 - $12,708	-6,169 Reduced 99.29%	44 $0
Q3 2023 Nov 15, 2023	SELL	$2.01 - $2.6 $10,920 - $14,125	-5,433 Reduced 46.65%	6,213 $12,000
Q1 2023 May 15, 2023	SELL	$1.95 - $2.54 $21,204 - $27,619	-10,874 Reduced 48.29%	11,646 $25,000
Q4 2022 Feb 14, 2023	BUY	$1.97 - $2.66 $21,378 - $28,866	10,852 Added 93.01%	22,520 $46,000
Q3 2022 Nov 14, 2022	SELL	$2.1 - $2.6 $7,692 - $9,523	-3,663 Reduced 23.89%	11,668 $25,000
Q2 2022 Oct 27, 2022	SELL	$2.31 - $3.14 $113 - $153	-49 Reduced 0.32%	15,331 $38,000
Q2 2022 Aug 15, 2022	SELL	$2.31 - $3.14 $113 - $153	-49 Reduced 0.32%	15,331 $38,000
Q1 2022 Oct 27, 2022	BUY	$2.19 - $2.81 $107 - $137	49 Added 0.32%	15,380 $41,000
Q1 2022 May 13, 2022	SELL	$2.19 - $2.81 $13,273 - $17,031	-6,061 Reduced 28.27%	15,380 $41,000
Q4 2021 Feb 14, 2022	SELL	$2.61 - $4.42 $28,895 - $48,933	-11,071 Reduced 34.05%	21,441 $57,000
Q3 2021 Nov 15, 2021	BUY	$3.4 - $4.24 $110,540 - $137,850	32,512 New	32,512 $123,000

4.83M

9.4K

Ticker MNOV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,046,200
Market Cap $106M
Description
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and ...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.